Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …

Background Individually tailored cancer treatment is essential to ensure optimal treatment
and resource use. Treatments for incurable metastatic non-small cell lung cancer (NSCLC) …

BACKGROUND: The recent approval of olaparib and niraparib as maintenance therapy can
significantly affect the management of ovarian cancer. Clinical benefits, however, come with …

Value-based care within insurance design utilizes evidence-based medicine as a means of
defining high-value versus low-value diagnostics and treatments. The goals of value-based …

BACKGROUND: In recent years, value assessment frameworks have been introduced to
inform discussions about how to define and assess value in the US health care system …

PURPOSE: Several frameworks have been developed to define and quantify the value of
oncologic therapies and to support decision making; however, they define treatment value …

Background Assessment of clinical benefit of systemic treatments of rare diseases including
gastroenteropancreatic neuroendocrine tumours (GEP-NET) is challenging. Recently …

If our aim is value-based radiotherapy, we must first understand and agree what constitutes
value. Generally speaking, value refers to importance, usefulness or (monetary) worth, ie …

Background Whether the high cost of cancer drugs is commensurate with their value to
patients, which has become the focus of public concern. We aimed to assess the value of …

Abstract Purpose Checkpoint (CTLA-4, PD-1, and PD-L1) inhibitors have changed the face
of oncology. A subset of patients enjoys long, gratifying treatment responses. Unfortunately …